Acetazolamide-responsive myotonia with a novel Ile239Thr mutation in SCN4A gene: a case report

• Published in: Annals of medicine and surgery 2024-02, Vol.86 (2), p.1191-1195
• Main Authors: Yadav, Jashpal, Barnwal, Ritesh, Kumar Mandal, Sujit, Prajapati, Bina
• Format: Article
• Language: English
• Subjects: Case Reports
• ISSN: 2049-0801; 2049-0801
• DOI: 10.1097/MS9.0000000000001673

Sodium channel myotonia (SCM) belongs to the group of sodium channelopathies with mutations involving gene. The main feature of sodium channel myotonia is pure myotonia without episodes of weakness or paralysis. One of the sodium channel myotonia has been classified as acetazolamide-responsive myotonia because of the effectiveness of acetazolamide as an antimyotonic drug. The child presented with generalized muscle hypertrophy and stiffness involving arms, thighs, calves, chest, and back muscles with unusually prominent trapezius muscle. The parents described the warm-up phenomenon as an improvement in stiffness as the day passes and with repetitive action. Percussion myotonia was illustrated in the thenar eminence and trapezius muscle. Characteristic 'dive-bomber' sound was present in electromyography, and whole-exome sequencing revealed a novel Ile239Thr mutation in the gene. Acetazolamide was prescribed for the condition, and regular follow-up shows an excellent clinical response. This case presents a pure myotonic phenotype without episodes of weakness or paralysis. Generalized myotonia with muscle hypertrophy and demonstrating warm-up phenomenon resembles myotonia congenita (a chloride channelopathy). However, genetic analysis revealed a novel Ile239Thr mutation involving gene indicating this case to be a sodium channelopathy. This case limelight sodium channel myotonia with a novel Ile239Thr mutation in gene that phenotypically resembles myotonia congenita but genetically belongs to sodium channelopathy highlighting the poor correlation between genotypes and phenotypes in non-dystrophic myotonia. Acetazolamide can be a safe and cost-effective antimyotonic drug in sodium channel myotonia.